CSIMarket
 


Strongbridge Biopharma plc  (SBBP)
Other Ticker:  
 

Strongbridge Biopharma Plc's Leverage Ratio

SBBP's quarterly Leverage Ratio and Total Liabilities, Equity growth


In Spite of the repayements of liabilities of -15.5%, in II Quarter 2021 ,Leverage Ratio deteriorated to 0.68, below the Strongbridge Biopharma Plc's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the second quarter 2021, 375 other companies have achieved lower Leverage Ratio than Strongbridge Biopharma Plc in the II Quarter 2021. While Leverage Ratio total ranking has deteriorated compared to the first quarter 2021 from 775 to 1805 .

Explain Leverage Ratio?
Who are SBBP Customers?
What are SBBP´s Total Liabilities?


SBBP Leverage Ratio (Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
(Sep 30 2020)
III. Quarter
(Jun 30 2020)
II. Quarter
Y / Y Equity Change -7.27 % -8.72 % -9.12 % -6.37 % -47.56 %
Y / Y Total Liabilities Change -6.21 % 68.31 % 46.4 % 2.57 % 20.76 %
Leverage Ratio MRQ 0.68 0.64 0.55 0.34 0.68
SBBP's Total Ranking # 1805 # 775 # 822 # 720 # 573
Seq. Equity Change -20.51 % -14.87 % -12.02 % 55.78 % -21.76 %
Seq. Total Liabilities Change -15.5 % 0.33 % 41.65 % -21.9 % 51.64 %



Leverage Ratio second quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 376
Healthcare Sector # 707
Overall Market # 1805


Leverage Ratio Statistics
High Average Low
87.25 5.51 0.07
(Mar 31 2018)   (Sep 30 2016)




Financial Statements
Strongbridge Biopharma Plc's Equity $ 44 Millions Visit SBBP's Balance sheet
Strongbridge Biopharma Plc's Total Liabilities $ 30 Millions Visit SBBP's Balance sheet
Source of SBBP's Sales Visit SBBP's Sales by Geography


Cumulative Strongbridge Biopharma Plc's Leverage Ratio

SBBP's Leverage Ratio for the trailling 12 Months

SBBP Leverage Ratio

(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
(Sep 30 2020)
III. Quarter
(Jun 30 2020)
II. Quarter
Y / Y Equity TTM Growth -7.27 % -8.72 % -9.12 % -6.37 % -47.56 %
Y / Y Total Liabilities TTM Growth -6.21 % 68.31 % 46.4 % 2.57 % 20.76 %
Leverage Ratio TTM 0.53 0.53 0.46 0.4 0.39
Total Ranking TTM # 1295 # 1289 # 1513 # 1109 # 944
Seq. Equity TTM Growth -20.51 % -14.87 % -12.02 % 55.78 % -21.76 %
Seq. Total Liabilities TTM Growth -15.5 % 0.33 % 41.65 % -21.9 % 51.64 %


On the trailing twelve months basis Due to repayements of liabilities of -15.5% Strongbridge Biopharma Plc has not changed Leverage Ratio in the 12 months ending in II Quarter 2021 to 0.53, below the company's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 285, during the past 12 months, other companies have achieved lower Leverage Ratio than Strongbridge Biopharma Plc. While Leverage Ratio total ranking has deteriorated during the twelve months ending in the II Quarter 2021, compared to the prior period, from 1289 to 1295.

Explain Leverage Ratio?
Who are SBBP Customers?
What are SBBP´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 286
Healthcare Sector # 523
Within the Market # 1295


trailing twelve months Leverage Ratio Statistics
High Average Low
23.69 2.24 0.07
(Dec 31 2017)   (Mar 31 2016)




Companies with similar Leverage Ratio in the quarter ending Jun 30 2021, within Major Pharmaceutical Preparations Industry Leverage RatioJun 30 2021 MRQ Total LiabilitiesJun 30 2021 MRQ Equity
Harmony Biosciences Holdings inc   1.84 $ 233.144  Millions$ 126.551  Millions
Collegium Pharmaceutical Inc   1.79 $ 452.298  Millions$ 253.066  Millions
Humanigen Inc  1.79 $ 78.035  Millions$ 43.695  Millions
Obseva Sa  1.75 $ 56.652  Millions$ 32.339  Millions
Urogen Pharma Ltd   1.73 $ 97.497  Millions$ 56.271  Millions
Merck and Co Inc   1.67 $ 55,905.000  Millions$ 33,388.000  Millions
Aditxt Inc   1.67 $ 9.941  Millions$ 5.964  Millions
Acer Therapeutics Inc   1.67 $ 12.956  Millions$ 7.777  Millions
Timber Pharmaceuticals Inc   1.64 $ 4.592  Millions$ 2.803  Millions
Grifols Sa  1.63 $ 13,346.745  Millions$ 8,195.150  Millions
Ocular Therapeutix Inc   1.62 $ 130.203  Millions$ 80.247  Millions
Mirum Pharmaceuticals Inc   1.59 $ 151.931  Millions$ 95.737  Millions
Viatris Inc   1.57 $ 33,291.500  Millions$ 21,206.900  Millions
Rapid Therapeutic Science Laboratories Inc   1.55 $ 0.617  Millions$ 0.396  Millions
Oncotelic Therapeutics Inc   1.54 $ 14.799  Millions$ 9.585  Millions
Heron Therapeutics Inc   1.52 $ 244.138  Millions$ 160.112  Millions
Prestige Consumer Healthcare Inc   1.51 $ 2,142.867  Millions$ 1,416.247  Millions
Ani Pharmaceuticals Inc  1.50 $ 288.242  Millions$ 191.917  Millions
Novan Inc   1.47 $ 47.390  Millions$ 32.326  Millions
Cv Sciences Inc   1.39 $ 13.877  Millions$ 9.977  Millions
Legend Biotech Corporation  1.37 $ 647.161  Millions$ 471.206  Millions
Molecular Templates inc   1.37 $ 133.354  Millions$ 97.402  Millions
Pfizer Inc  1.36 $ 95,717.000  Millions$ 70,315.000  Millions
Athersys Inc  1.36 $ 42.254  Millions$ 31.046  Millions
Avadel Pharmaceuticals Plc  1.36 $ 161.628  Millions$ 118.880  Millions
Johnson and Johnson  1.36 $ 94,410.000  Millions$ 69,580.000  Millions
Landec Corporation  1.33 $ 270.389  Millions$ 202.784  Millions
Catalent Inc   1.33 $ 5,197.000  Millions$ 3,915.000  Millions
Insmed Inc  1.32 $ 698.730  Millions$ 531.053  Millions
Evelo Biosciences Inc   1.31 $ 81.153  Millions$ 62.093  Millions

Date modified: -0001-11-30T00:00:00+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com